Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER (PFE)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about PFIZER
10/17 PFIZER INC. (NYSE : PFE) Phase II Clinical Trial Of Lorlatinib Shows Promise
10/17 PFIZER INC. : - The Union for International Cancer Control and Pfizer award
10/17DJDaimler Charts Leaner Approach -- WSJ
10/16DJDaimler Reshapes Company to Meet Challenges of Changing Industry -- Update
10/16 PFIZER : Presents Full Results from Phase 2 Study of Next-Generation Investigati..
10/16 PFIZER INC. : - U.S. FDA Approves LYRICA CR Extended Release Tablets CV
10/16 Stocks mostly up
10/14 PFIZER : FG - Ignorance Responsible for High Cancer Mortality Rate
10/13 PFIZER : The Union for International Cancer Control and Pfizer award new round o..
10/13 PFIZER INC. (NYSE : PFE) Lyrica CR Approved By FDA As Patent Expiry Date Nears
10/13 PFIZER : Brazil, Russia And India Offer The Best Opportunities In The Musculoske..
10/13 PFIZER : CordenPharma Acquires Pfizer API Manufacturing Facility in Boulder Colo..
10/12 PFIZER : U.S. FDA Approves LYRICA® CR (pregabalin) Extended-Release Tablets CV
10/12 PFIZER : Reviewing Strategic Alternatives for Consumer Healthcare Business
10/12 PFIZER : How to Create an Integrated Social Media and Digital Strategy for Patie..
More most relevant news
All news about PFIZER
10/17 PFIZER INC. (NYSE : PFE) Phase II Clinical Trial Of Lorlatinib Shows Promise
10/17 PFIZER : Presents Full Results From Phase 2 Study of Next-Generation Investigati..
10/17 PFIZER : New Ulcerative Colitis Data For Xeljanz (Tofacitinib) At Upcoming Gastr..
10/17 PFIZER : After getting skunked by rivals, Pfizer touts breakthrough cancer drug ..
10/17 PFIZER INC. : - The Union for International Cancer Control and Pfizer award
10/17DJDaimler Charts Leaner Approach -- WSJ
10/16 PFIZER : Health and Human Services Department (HHS); Food and Drug Administratio..
10/16DJDaimler Reshapes Company to Meet Challenges of Changing Industry -- Update
10/16 PFIZER : Presents Full Results from Phase 2 Study of Next-Generation Investigati..
10/16 PFIZER INC. : - U.S. FDA Approves LYRICA CR Extended Release Tablets CV
More news
Sector news : Pharmaceuticals - NEC
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
10/17 Amneal, Impax combine to tackle generic drug pricing pressure
10/17 FTSE inches down, Merlin collapses on poor summer trading
10/17DJHUTCHISON CHINA MEDITECH : AstraZeneca Say Drug Shows Potential to Treat Lung Ca..
10/17DJASTRAZENECA : FDA Accepts Imfinzi Supplemental Biologics License Application; Gr..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/17 YOUR DAILY PHARMA SCOOP : Everybody's Gilead Problem, Halozyme's Further Progres..
10/17 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 17, 2017
10/16 President Trump at it again with comments on "out of control" drug prices
10/16 Don't Believe The Hype
10/16 Pfizer's lorlatinib shows treatment effect in mid-stage lung cancer study
10/15 DIVIDEND INCOME UPDATE : September 2017
Latest Tweets
10/17Excited 2b representing @dnanexus at @pfizer #EX2017 innovation conference+wo.. 
10/17[SPONSORED] As the U.S. healthcare system evolves, patients need guidance. Pf..
6
10/17Get ready for precision and invasive pharmaceutical ads $PFE  
10/17Pfizer, NEA back Cydan's plans to launch a fresh slate of biotech startups fo..
2
10/17Pfizer, NEA back Cydan II’s plans to launch a fresh slate of biotech startups..
1
More tweets
Qtime:353
Financials ($)
Sales 2017 52 676 M
EBIT 2017 19 837 M
Net income 2017 12 051 M
Debt 2017 24 101 M
Yield 2017 3,56%
P/E ratio 2017 19,34
P/E ratio 2018 17,00
EV / Sales 2017 4,53x
EV / Sales 2018 4,33x
Capitalization 214 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 38,2 $
Spread / Average Target 6,2%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Dennis Arthur Ausiello Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER11.88%214 265
JOHNSON & JOHNSON18.42%365 346
NOVARTIS13.23%226 956
ROCHE HOLDING LTD.5.20%215 359
MERCK AND COMPANY7.68%172 751
AMGEN25.17%132 728